Final results of a randomized Phase II trial have been announced for the new parp-inhibitor drug Iniparib. Results are somewhat encouraging. The trial enrolled triple-negative breast cancer patients with metastatic disease, assigning them to receive iniparib plus chemotherapy (gemcitabine/carboplatin) or chemotherapy alone.
Triple-negative breast cancer is a type of cancer with tumors that aren't receptive to estrogen and progesterone and test negative for the Her 2 oncogene. Patients with triple-negative breast cancer usually have a poorer prognosis and shorter survival. About 15% of all breast cancer cases are triple negative.
Of the patients who received Iniparib + chemo, 55.7% experienced complete or partial response over 6 months compared to 33.9% of patients who received chemo alone.
The results are encouraging, offering the possibility of a new treatment for metastatic triple negative breast cancer patients. Treatment options for this group of women is currently limited.